FORMULATION AND EVALUATION OF COMPRESSION COATING FLOATING TABLETS OF CARVEDILOL PHOSPHATE ONCE DAILY DOSE
Objective: The rationale for the study was to develop a once-daily dose of immediate as well as a gastro-retentive form of carvedilol phosphate by compression coating floating technique.
Methods: In the presented study the core tablet was containing half the quantity of the drug formulated as floating drug delivery using different controlled release polymers blend in various proportions like ethyl cellulose, carbopol, hydroxypropyl methylcellulose (HPMC) K4, K15, and K100 by direct compression method. Outer coat layer was formulated with rest of the drug with the blend of different super disintegrants in various proportions like crospovidone, croscarmellose sodium (CCS), sodium starch glycolate (SSG) for the immediate release of the drug. Both the immediate and controlled formulation was separately formulated from sf1 to sf9 and f1 to f9 respectively. Based on the evaluation parameters finally, formulation F1 to F9 were formulated by applying compression coating floating method. These formulations were characterized for their tablet density, disintegration time, floating lag time, in vitro drug release, drug-excipients interaction and accelerated stability studies etc.
Results: The result revealed formulation sf9 containing SSG of 15% was able to 97.2% of drug release within 15 min towards the achievement of immediate release. Similarly, the formulation f9 containing 0.5:0.5:4.5 ratios of ethyl cellulose, carbopol and HPMC K15 was able to 95.3% of drug release within 16h. From compressed coat tablets batches of F1 to F9, based on the dissolution data F9 was considered as an optimized formulation which was able to release 48.6% of drug release within 15 min and cumulatively controlled the release up to 96.4% for 16 h, followed zero-order kinetics and Higuchi pattern.
Conclusion: The results obtained in this research work clearly indicated that the compression coating floating tablet of carvedilol phosphate was the best dosage form for the treatment of hypertension. Results of the evaluation of prepared batches indicate that the batch F9 is a promising formulation for both a quick onset of action as well as gastro-retentive dosage form to maintain the constant drug action which would improve the maximum therapeutic efficacy and patient compliance.
2. Kadam VD, Gattani SG. Dissolution enhancement of carvedilol by using a surfactant as a coating material. Asian J Pharm Clin Res 2009;2:39-43.
3. Patel H, Patel MM. Formulation and evaluation of the controlled porosity osmotic drug delivery system of carvedilol phosphate. J Pharm Sci Biosci Res 2012;2:77-82.
4. Nayak AK, Maji R, Das B. Gastroretentive drug delivery systems a review. Asian J Pharm Clin Res 2010;3:2-10.
5. Chaudhari S, Bawaskar M, Shirsat A. Formulation and evaluation of carverdilol phosphate. J Drug Delivery Ther 2012;2:9-19.
6. Sakhare SS, V Yadav V, Jadhav D. Design, development and characterization of mucoadhesive gastro spheres of carvedilol. Int J App Pharm 2016;8:37-42.
7. Pisipati A, Lyadella D, Kalva B, Subrahmanyam CVS. Formulation and In vitro evaluation of carvedilol transdermal delivery system. Tropical J Pharm Res 2013;12:461-7.
8. Tekade BW, Jadhao UT, Patil SG, Patil VR. Formulation and in vitro evaluation of floating tablets of cefpodoxime proxetil. Int J Curr Pharm Res 2017;9:18-22.
9. Shah HP, Prajapati ST, Patel CN. Gastroretentive drug delivery systems: from conception to commercial success. J Crit Rev 2017;4:10-21.
10. Ramu B, Pandiyan S. Formulation and evaluation of gastroretentive floating bioadhesive tablets of hydrochlorothiazide. Asian J Pharm Clin Res 2017;10:150-5.
11. Ravala JA, Patela JK, Naihong L, Patela MM. Ranitidine hydrochloride floating matrix tablets. Asian J Pharm Sci 2007;2:130-42.
12. Yeole PG, Khan S, Patel VF. Floating drug delivery systems: need and development. Indian J Pharma Sci 2005;67:265-72.
13. Sharma F, Jain H, Kanzariya V, Upadhyay U. Formulation and evaluation of controlled release osmotic tablet of metoprolol succinate. Asian J Pharm Clin Res 2014:7:38-43.
14. Chein YW. Novel drug delivery systems. 2nd edn. Marcel Dekker, New York 1992. p. 18-139.
15. Lachmann L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. 3rd edn. Varghese Publishing House, Bombay; 1991. p. 430-45.
16. Halder S, Hasan M, Das BK, Kalam A, Kabir L, Shara A, et al. In vitro release study of carvedilol phosphate matrix tablets prepared with hydroxypropyl methylcellulose. Trop J Pharma Res 2012;11:379-86.
17. Singh BN, Kim KH. Floating drug delivery system: an approach to oral controlled drug delivery via gastric retention. J Controlled Release 2000;63:235-59.
18. Gronia R, Heun G. Oral dosage forms with controlled gastrointestinal transit. Drug Dev Ind Pharm 1984;10:527-39.
19. Harekrishna Roy. Formulation of sustained release matrix tablets of metformin hydrochloride by polyacrylate polymer. Int J Pharma Res Health Sci 2015;3:900-6.
20. Dhirendra K, Vivek D, Shaila L, Brajesh P, Kavita R Gajbhiye, Sarvesh Paliwal. Design and evaluation of sustained release matrix once daily formulation of Stavudine. Int J Drug Delivery 2010;2:125-34.
21. U. S. Department of Health and Human Services [Internet]. Silver Spring, Maryland: Guidance for industry. Q1A (R2) stability testing of new drug substances and products; 2003. p. 4-5.